These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 25590803)

  • 21. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
    Mazumder S; Choudhary GS; Al-Harbi S; Almasan A
    Cancer Res; 2012 Jun; 72(12):3069-79. PubMed ID: 22525702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S; Dai Y; Pei XY; Grant S
    Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
    Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
    Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
    Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
    Wang Q; Wan J; Zhang W; Hao S
    Leuk Lymphoma; 2019 Sep; 60(9):2170-2180. PubMed ID: 30626241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
    Peperzak V; Slinger E; Ter Burg J; Eldering E
    Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mcl-1 expression and JNK activation induces a threshold for apoptosis in Bcl-xL-overexpressing hematopoietic cells.
    Zhang Y; Li X; Tan S; Liu X; Zhao X; Yuan Z; Nie C
    Oncotarget; 2017 Feb; 8(7):11042-11052. PubMed ID: 28038464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
    Tanos R; Karmali D; Nalluri S; Goldsmith KC
    BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Rooswinkel RW; van de Kooij B; Verheij M; Borst J
    Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.
    Spender LC; Inman GJ
    Mol Cancer Res; 2012 Mar; 10(3):347-59. PubMed ID: 22241218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
    Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
    Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies.
    Al-Harbi S; Choudhary GS; Ebron JS; Hill BT; Vivekanathan N; Ting AH; Radivoyevitch T; Smith MR; Shukla GC; Almasan A
    Mol Cancer; 2015 Nov; 14():185. PubMed ID: 26537004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.
    Preuss E; Hugle M; Reimann R; Schlecht M; Fulda S
    J Biol Chem; 2013 Dec; 288(49):35287-96. PubMed ID: 24133218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.
    Jane EP; Premkumar DR; DiDomenico JD; Hu B; Cheng SY; Pollack IF
    Mol Cancer Ther; 2013 Mar; 12(3):326-38. PubMed ID: 23325792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.